WallStreetZenWallStreetZen

NASDAQ: BCDA
Biocardia Inc Stock

$0.39+0.00 (+0%)
Updated May 20, 2024
BCDA Price
$0.39
Fair Value Price
-$0.26
Market Cap
$10.70M
52 Week Low
$0.32
52 Week High
$2.92
P/E
-0.83x
P/B
-4.7x
P/S
21.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$468.00k
Earnings
-$10.34M
Gross Margin
100%
Operating Margin
-2,208.76%
Profit Margin
-2,208.8%
Debt to Equity
-2.18
Operating Cash Flow
-$9M
Beta
0.52
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BCDA Overview

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BCDA ($0.39) is overvalued by 251.45% relative to our estimate of its Fair Value price of -$0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCDA ($0.39) is not significantly undervalued (251.45%) relative to our estimate of its Fair Value price of -$0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCDA due diligence checks available for Premium users.

Be the first to know about important BCDA news, forecast changes, insider trades & much more!

BCDA News

Valuation

BCDA fair value

Fair Value of BCDA stock based on Discounted Cash Flow (DCF)
Price
$0.39
Fair Value
-$0.26
Undervalued by
250.67%
BCDA ($0.39) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCDA ($0.39) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BCDA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.83x
Industry
8.16x
Market
31.12x

BCDA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-4.7x
Industry
6.06x

BCDA's financial health

Profit margin

Revenue
$55.0k
Net Income
-$2.3M
Profit Margin
-4,121.8%
BCDA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BCDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$2.7M
Liabilities
$5.0M
Debt to equity
-2.18
BCDA's short-term liabilities ($4.07M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCDA's short-term assets ($1.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.5M
Investing
$0.0
Financing
$1.4M
BCDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BCDA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BCDA$10.70M0.00%-0.83x-4.70x
BNOX$10.59M+1.66%0.03x0.55x
MNPR$10.84M+1.64%-1.19x1.45x
ONVO$10.84M+4.85%-0.50x1.75x
CHRO$10.50M+4.00%-0.26x9.29x

Biocardia Stock FAQ

What is Biocardia's quote symbol?

(NASDAQ: BCDA) Biocardia trades on the NASDAQ under the ticker symbol BCDA. Biocardia stock quotes can also be displayed as NASDAQ: BCDA.

If you're new to stock investing, here's how to buy Biocardia stock.

What is the 52 week high and low for Biocardia (NASDAQ: BCDA)?

(NASDAQ: BCDA) Biocardia's 52-week high was $2.92, and its 52-week low was $0.32. It is currently -86.58% from its 52-week high and 22.5% from its 52-week low.

How much is Biocardia stock worth today?

(NASDAQ: BCDA) Biocardia currently has 27,304,116 outstanding shares. With Biocardia stock trading at $0.39 per share, the total value of Biocardia stock (market capitalization) is $10.70M.

Biocardia stock was originally listed at a price of $1,738.17 in Dec 31, 1997. If you had invested in Biocardia stock at $1,738.17, your return over the last 26 years would have been -99.98%, for an annualized return of -27.6% (not including any dividends or dividend reinvestments).

How much is Biocardia's stock price per share?

(NASDAQ: BCDA) Biocardia stock price per share is $0.39 today (as of May 20, 2024).

What is Biocardia's Market Cap?

(NASDAQ: BCDA) Biocardia's market cap is $10.70M, as of May 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biocardia's market cap is calculated by multiplying BCDA's current stock price of $0.39 by BCDA's total outstanding shares of 27,304,116.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.